Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT03044847

The Cohort Study for Chronic Obstructive Pulmonary Disease (COPD) in China

The purpose of this study is to establish the large COPD cohort and biological database in China, aiming for precision medicine to optimize diagnosis and treatment choices and to monitor and improve clinical outcomes in this disease.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

40 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Capital Medical University

Beijing, Beijing Municipality, China

About this study

This is a 5-year multi-center observational prospective longitudinal cohort study to to establish the large COPD cohort and biological database in China, including COPD subjects( n= 3000) and GOLD 0 subjects (n= 800).Sites Investigators will be respiratory physicians working in the respiratory department of our sites, which must be tier 2 or tier 3 hospitals in China, with the equipment and ability to conduct pulmonary function test, HRCT.Patients must meet all the inclusion criteria and none of the exclusion criteria.No additional investigational drugs will be applied to the patients. Full analysis set will be used for all analyses. Missing data will be analysed as it is. Statistical analysis will be conducted by epidemiology & statistics work group from Chinese Academy of Sciences, using SAS and SUDAAN software. An electronic data capture system will be used in this study. Paper-based questionnaire administration will also be used.Questionnaire variables will be checked before data entry.During the study, PI will be in charge of the monitoring of the whole procedure. Two working group will do the data cleaning and data analysing.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 40-75 years
  • COPD group: baseline post-bronchodilator FEV1/FVC < 0.7
  • GOLD 0 group: individuals with chronic respiratory symptoms and/or high risk factors
  • Signed informed consent obtained prior to participations with the ability to comply with protocol and be available for study visits over 5 years

Exclusion criteria

  • Acute exacerbation in the past 3 months
  • Having other respiratory diseases with massive lung tissue destruction such as severe bronchiectasis and tuberculosis, etc
  • The usual criteria of serious uncontrolled diseases
  • thoracic or abdominal surgery in the last 3 months
  • eye surgery in the last three months
  • retinal detachment
  • myocardial infarction in the last 3 months
  • admission to hospital for any cardiac condition in the last month
  • heart rate over 120 beats per minute
  • antibacterial chemotherapy for tuberculosis
  • pregnant or breast feeding

Treatment and study plan

COPD group

Other

The treatments will be determined by their treating physicians and no additional investigational drugs will be applied to the patients included in this study.

Primary outcomes

  1. COPD-related mortality and all-cause mortality

    Time frame: 10 years

    COPD-related mortality and all-cause mortality

Secondary outcomes

  1. COPD exacerbation rate per year

    Time frame: 10 years

    COPD exacerbation rate per year

Sponsors and collaborators

Lead sponsor

Beijing Chao Yang Hospital

Other

Registry information

Official study title

The Cohort Study for Chronic Obstructive Pulmonary Diseases (COPD) in China---- Observation of the Disease Outcome and Identification of Prognostic Biomarkers for the Disease Outcome

Important dates

Study start
2016
Primary completion
2028
Study completion
2028
First posted
Feb 7, 2017
Registry last updated
Jul 29, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.